Archives
-
SB-3CT, MMP9, and Cortical Plasticity
2026-10-19
A mouse visual-cortex study links PV-interneuron Adamtsl3 loss to MMP9 dysregulation, perineuronal-net disruption, and renewed adult cortical plasticity. The associated SB-3CT evidence supports MMP9-pathway involvement but does not establish exclusive MMP9 specificity, brain exposure, or applicability to human schizophrenia.
-
Deoxycholic Acid Sodium Salt: Evidence Boundaries
2026-10-18
The APExBIO listing identifies SKU C6885 as deoxycholic acid sodium salt, but the supplied product information contains no description, matched research paper, mechanism statement, measurement principle, or outcome data. Accordingly, the material’s documented identity can be discussed only at a basic naming level; its biological activity, analytical role, performance, and applicability remain unestablished by the available evidence.
-
Adamtsl3, MMP9, and Adult Cortical Plasticity
2026-10-17
A mouse study places Adamtsl3 at the intersection of perineuronal-net maintenance, MMP9 regulation, and adult visual-cortex plasticity. The evidence supports MMP9 as an important mediator, while the dual gelatinase activity of SB-3CT and the limits of mouse and marker-based evidence argue against treating the pharmacological rescue as proof of an MMP9-exclusive or human schizophrenia mechanism.
-
Ionomycin Calcium Salt: Evidence and Scope
2026-10-16
A source-bounded overview of Ionomycin calcium salt as a calcium ionophore, distinguishing the product page’s mechanistic claims and model-specific findings from independently verified research evidence.
-
Ionomycin Calcium Salt: Evidence and Scope
2026-10-16
APExBIO describes ionomycin calcium salt as a calcium ionophore that elevates intracellular Ca2+ by mobilizing regulated calcium pools and promoting extracellular influx. The same product description associates this perturbation with protein-synthesis and secretion readouts, apoptosis-related findings in HT1376 bladder cancer cells, and reduced tumor growth in a nude-mouse model. Because no identity-matched paper, DOI, sample size, effect size, or uncertainty estimate is provided, these claims remain source-attributed product information rather than independently verifiable evidence.
-
Ionomycin Calcium Salt: Evidence and Scope
2026-10-15
A source-bounded overview of Ionomycin calcium salt as a calcium ionophore, distinguishing catalog-described mechanisms and model findings from identity-matched research evidence. The available information supports interpretation of calcium signaling, secretion, protein-synthesis, and apoptosis readouts, but does not establish product-specific efficacy, selectivity, or clinical relevance.
-
Bardoxolone Methyl: Mechanism and Evidence Boundaries
2026-10-15
Bardoxolone methyl, also called CDDO methyl ester, is described by APExBIO as a synthetic oleanane triterpenoid associated with Nrf2 pathway activation and NF-kB pathway inhibition. The supplied product information reports downstream antioxidant and inflammatory readouts, leukemia-cell IC50 values, kidney- and lung-disease model findings, and a history of clinical development in chronic kidney disease. Because no identity-matched paper is available here, these claims should be treated as product-page documentation rather than independently verified research evidence.
-
Haloprogin: Identity, Mechanism, and Evidence Limits
2026-10-14
Haloprogin, identified by the APExBIO product page as 1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene, is described as a topical antifungal and selective anti–Gram-positive antimicrobial. The same source reports low MIC values against selected dermatophytes, Candida albicans, Staphylococcus aureus, and Streptococcus pyogenes, while acknowledging that the molecular targets remain unresolved. Because no identity-matched research paper is available here, these findings should be treated as product-page claims rather than independently verifiable study results.
-
Adamtsl3, MMP9 and Perineuronal-Net Plasticity
2026-10-14
A mouse study links the schizophrenia-associated gene Adamtsl3 to perineuronal-net integrity, MMP9 regulation and adult cortical plasticity. The findings support a mechanistic model in visual cortex, but they do not establish a human disease mechanism or show that SB-3CT produced the reported effects.
-
CA-074 and Cathepsin B Evidence in Necroptosis
2026-10-13
A 2024 study links MLKL polymerization to lysosomal membrane permeabilization and identifies cathepsin B as an important contributor to necroptotic cell death. The findings support a role for cathepsin B in the studied human cell model, but they do not establish that CA-074 was the inhibitor used or that vendor-reported selectivity translates across models.
-
SB 431542 and Enteric Neuronal Injury: Evidence Limits
2026-10-13
A source-grounded overview of how the reported MMP8–TGF-β mechanism in enteric neuronal injury relates to the supplier-described ALK5 inhibitor SB 431542, with emphasis on evidence boundaries, pharmacologic specificity, and translational limitations.
-
How Vaccinia F1L Evades NLRP1 Signaling
2026-10-12
Szymanska and colleagues report that the vaccinia protein F1L suppresses ZAKα-linked, ribotoxic-stress activation of the NLRP1 inflammasome in cellular models, while leaving DPP9-inhibition-mediated activation comparatively intact. The findings support a viral-evasion model but remain limited by their reliance on modified vaccinia virus and in vitro systems.
-
Dantrolene and CRISPR Repair: Evidence Gaps
2026-10-12
The 2025 CRISPR drug-repurposing study reports a large phenotypic screen for compounds associated with different DNA-repair outcomes, but the supplied evidence does not establish Dantrolene sodium salt as a validated hit or connect ryanodine receptor antagonism with repair-pathway choice. Interpretation is therefore limited by screening design, pathway proxies, cell context, and the absence of compound-specific validation.
-
Thapsigargin: Evidence, Scope, and ER Stress
2026-10-11
Thapsigargin is a SERCA pump inhibitor used as a mechanistic perturbation tool in calcium signaling and endoplasmic reticulum stress research. The supplied evidence supports a conceptual link between SERCA inhibition, altered intracellular calcium homeostasis, unfolded protein responses, and apoptosis, but does not establish clinical benefit or validate every supplier-reported application.
-
Resiniferatoxin (RTX): Evidence and Research Context
2026-10-10
Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist being investigated as a localized, long-acting approach to pain modulation. Current evidence supports a biologically plausible mechanism and encouraging preclinical findings, but human evidence remains preliminary and application-specific.